3 Key Things Every Car-t Investor Should Watch

A long-awaited breakthrough in cancer treatment, chimeric antigen receptor T-cell (CAR-T) therapy, could finally hit the market later this year.First-to-market advantage will likely to go Novartis (NYSE: NVS) with its drug named CTL019. Recently, a panel of FDA advisors unanimously recommended approval for CTL019, which will likely receive a final stamp of approval from the agency by early October.

BING NEWS:
  • Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
    Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune ...
    04/22/2024 - 11:30 am | View Link
  • mRNA Therapeutics Market is Estimated to be USD 45.85 billion by 2031; Driven by Innovative Therapeutic Potential
    RNA Therapeutics Market is Estimated to be USD 4585 billion by 2031 Driven by Innovative Therapeutic Potential ...
    04/19/2024 - 5:42 am | View Link
  • Imugene and Kincell Bio Announce Strategic Manufacturing and Process Development Partnership
    Kincell Bio to acquire Imugene’s North Carolina manufacturing facility for up to $6M USD in upfront and milestone-driven payments over three ...
    04/16/2024 - 12:19 am | View Link
  • Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript
    Q4 2023 Earnings Call Transcript March 25, 2024 Theriva Biologics, Inc. beats earnings expectations. Reported EPS is $-0.34, expectations were $-0.41. Theriva Biologics, Inc. isn’t one of the 30 most ...
    03/25/2024 - 9:42 pm | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News